Cell-El, The ASD Bio-marker Company
Cell-El’s breakthrough research of diagnostic bio-markers should lead to more objective and earlier diagnosis of ASD. This is paving the way for earlier intervention, better outcomes and the testing of promising new therapies including stem cells and modulation of the microbiome.
DIAGNOSTICS
Your child’s participation in Cell-El’s successful clinical diagnostic study of young children is paving the way to targeted effective therapy and the possibility of earlier intervention.
THERAPY
Cell-El delves beyond the behavioral observation of ASD to its underlying biological mechanisms. Our diagnostic findings provide the rationale for targeted treatments.
JOIN OUR TEAM
- Was your child diagnosed with ASD?
- Are you interested in joining a breakthrough diagnostic study which could lead to the earlier intervention and the development of new tools to monitor the effects of therapy.
Parents and clinicians join the Cell-El team in its multi-national clinical collaborations which have approvals from the Helsinki ethics committees and the Israeli Ministry of Health.
- Dr. Gesundheit brings his scientific and clinical experience from The Hospital for Sick Children, Toronto, Canada, the department of Pediatric Hematology-Oncology at Soroka Hospital Beer Sheva, Israel and Hadassah Hospital, Jerusalem Israel to his methodical research in ASD and its immunological aspects as well as to the rationale for the treatment with stem cells.
BENI GESUNDHEIT, MD PhD
Dr. Samuels has over 36 years of senior management experience in startup, mid size and large companies in the in vitro diagnostic (IVD) industry including Orgenics, Alere and Abbott. He has led the development, manufacturing and CE and FDA approval of many in vitro diagnostics (IVD) products.
Fred Samuels, PhD
Dr. Ellis has 35 years of senior management experience for R&D companies – large, medium, small, startup and incubators. His development and project leadership skills have brought therapeutics to the clinic and to market.
Ronald Ellis, PhD MBA
Mr. Labinsky has extensive experience and planning in working with companies in business, corporate and investment management. Baruch is licensed by the Israel Securities Authority as an investment portfolio manager.
Baruch Labinsky, MA
A strategic thinker and contingency planner, Dr Piwko has the analytical skills for integrating and interpreting interdisciplinary projects. He has 20 years of experience conducting health economic research for the pharma, biotech, and medical devices industry.
Charles Piwko, PhD
Mrs. Hochbaum has over 20 years of experience working with families of children with ASD. She speaks with parents and clinicians about our ASD diagnostic study, thereby enabling our research. Speak with Leah if you want to join our team and work together at solving the autism challenge!
LEAH HOCHBAUM, MA OTR/L
Dr. Zisman has over ten years of experience in the fields of biotechnology, biochemistry, cell biology, immunology, and bioassays. He is responsible for laboratory issues, assay development and immunology.
Philip David Zisman, PhD
Dr. Posen consults at Cell-El, and prepares clinical trial-related documents and manuscripts for publication. She brings over ten years of experience as a medical and scientific writer, supporting both academic researchers and pharmaceutical and medical device R&D teams.
Yehudit Posen, PhD
Dr. Refoel Guggenheim is a clinical pediatrician affiliated at the Triemli Hospital Zurich, Switzerland. He focuses on pediatric developmental medicine and Allergy/Clinical Immunology. He is engaged in Medical Ethics and organizes Conferences on Jewish Medical Ethics. He is co-editor of the pediatric journal Kinderärzte Schweiz.
Refoel Guggenheim, MD
Ms. Ansel’s Master’s thesis research of Immunogenetics with a focus on genetic variation in non-human primates as well as her work in genetics, immunology and neuroscience labs in the USA and Israel, have been a big asset to her work at Cell-El.
Ashley Ansel, MA
Mrs. Suna has over 20 years of web design and development experience with small to large organizations as well as pharmaceutical companies. Susan works closely with the team crafting the website and its messaging.
Susan Suna, MA
Parents Ask
Cell-El’s research shows an important association between the immune system and ASD. These findings are the basis for targeted treatments. For more information please read our Diagnostics page.
The entire procedure takes less than an hour. It involves:
- Signing a consent form
- Filling out a medical questionnaire with a team member
- Drawing up to 5 ml venous blood
- The child does not have to fast
The diagnostic test involves drawing about 5 ml of venous blood and this standard procedure has minimal risk.
- Sign Up
We look forward to your participation in the Cell-El diagnostic study. Please read the information below regarding the inclusion and exclusion criteria for the following cohorts: 1. Infants and their mothers and 2. Children pre and post Stem Cell Therapy (SCT). Then please fill out the appropriate form.
- Cohort of infants and their mothers: Mothers of high-risk infants and infants aged 10-18 months not diagnosed with ASD but with a sibling diagnosed with ASD according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (299.00) or DSM-V (299.00) ± ADOS (herein termed “high-risk infants”) or
- Cohort of children pre and post SCT: Male and female children age 2-12 years Diagnosed autism spectrum disorder (ASD) according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (299.00) or DSM-V (299.00) undergoing stem cell therapy.
- For both cohorts: Informed consent signed by the parents
- For both cohorts: Child and/or mother that have been treated with systemic steroids or have undergone immune suppression treatment within the last 6 months
- Child and/or mother diagnosed with severe infectious diseases or sepsis over the last 6 months
- Child and/or mother with hematological or malignant disorder
- For children in the SCT cohort: No new planned treatment (other than SCT) for at least 6 months from planned stem cell transplantation date and no new treatments (other than SCT) started within 6 months before planned transplantation date.
- Child with ASD treated for a severe convulsive disorder
If you are a parent or a clinician of a child diagnosed with ASD, please click here to fill out the appropriate form.
- More Information
Read our research and peer reviewed articles. For any additional questions, please fill out the form below
- Published February 2023:Autism Spectrum Disorder Diagnosis using a New Panel of Immune – and Inflammatory – Related Serum Biomarkers: A Case-Control Multicenter Study, Frontiers in Pediatrics
- Autism Spectrum Disorders (ASD) – Searching For the Biological Basis For behavioral Symptoms And new Therapeutic Targets, Frontiers in Neuroscience and Frontiers in Pediatrics
- Immunological and autoimmune considerations of Autism Spectrum Disorders, Journal of Autoimmunity
To receive more information, please fill out the form below.